Ignite Creation Date:
2025-12-24 @ 2:11 PM
Ignite Modification Date:
2025-12-28 @ 6:09 AM
Study NCT ID:
NCT06709495
Status:
RECRUITING
Last Update Posted:
2025-02-13
First Post:
2024-11-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Sponsor:
David S Shulman, MD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-01-27
Start Date Type:
ACTUAL
Primary Completion Date:
2028-11-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-11-17
First Submit QC Date:
None
Study First Post Date:
2024-11-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-11
Last Update Post Date:
2025-02-13
Last Update Post Date Type:
ACTUAL